$TEM Tempus AI — Clean Setup After Personalis News
Two pharma giants (Merck + Moderna) just validated personalized cancer vaccines in a major skin cancer trial. Each vaccine is custom-built from tumor DNA sequencing.
Tempus is acquiring Personalis — a company that runs those exact tumor DNA tests. The market is pricing in the strategic fit.
Chart Structure:
Triple bottom confirmed. Volume shelf launch in play — that's your base, your accumulation zone that now wants to run.
Options flow shows $60 and $65 as resistance caps. Floor sits around $50 — that's your invalidation if this thesis breaks.
Setup: Long above the shelf with $50 as your line in the sand. First target $60, extended $65. If it loses $50, the structure fails and you're out.
This is how you read a catalyst with structure — news confirms the thesis, chart confirms the entry.
Two pharma giants (Merck + Moderna) just validated personalized cancer vaccines in a major skin cancer trial. Each vaccine is custom-built from tumor DNA sequencing.
Tempus is acquiring Personalis — a company that runs those exact tumor DNA tests. The market is pricing in the strategic fit.
Chart Structure:
Triple bottom confirmed. Volume shelf launch in play — that's your base, your accumulation zone that now wants to run.
Options flow shows $60 and $65 as resistance caps. Floor sits around $50 — that's your invalidation if this thesis breaks.
Setup: Long above the shelf with $50 as your line in the sand. First target $60, extended $65. If it loses $50, the structure fails and you're out.
This is how you read a catalyst with structure — news confirms the thesis, chart confirms the entry.